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The increasing prevalence of quinolone-resistant
Neisseria gonorrhoeae (QRNG) in the United States is a
cause for concern. Detecting resistance is complicated by
the widespread use of molecular tests that do not provide
isolates for susceptibility testing. The Michigan Department
of Community Health developed a sentinel surveillance
program to detect antimicrobial drug resistance in N. gon-
orrhoeae. Sentinel surveillance from 11 laboratories sub-
mitted 1,122 isolates for antimicrobial drug susceptibility
testing and detected 2 clusters of QRNG from January
2003 to September 2004. These clusters were epidemio-
logically distinct: one involved young, heterosexual youth,
and the other involved older men who have sex with men.
This finding led to changes in local treatment recommenda-
tions that limited spread of resistant strains. Development
of the sentinel program, collection of data, and epidemio-
logic analysis of the clusters are discussed.
S
ince the 1970s, the treatment and control of gonorrhea
have been complicated by the ability of Neisseria gon-
orrhoeae to develop resistance to a variety of antimicrobial
agents, including penicillin, tetracycline, and fluoro-
quinolones. Recent limitations in oral treatments for gon-
orrhea resulting from the discontinued manufacturing of
cefixime, as well as decreases in the availability of isolates
for susceptibility testing as culture methods are replaced
by nucleic acid amplification tests, pose additional chal-
lenges for successfully treating patients and identifying
resistant organisms. 
In 1986, the then-Centers for Disease Control (CDC)
established the Gonococcal Isolate Surveillance Project
(GISP) to monitor changes in antimicrobial drug–suscepti-
bility patterns. Twenty-five isolates are collected monthly
from participating sexually transmitted disease (STD) clin-
ics across the United States (30 cities represented in 2003)
and are sent to CDC for susceptibility testing (1). 
In the early 1990s, fluoroquinolone-resistant N. gonor-
rhoeae (QRNG) was reported from a number of areas out-
side of the United States, and resistant strains became well
established in Thailand, Hong Kong, Japan, and the
Philippines. Sporadic reports of QRNG in the United
States at that time were usually associated with travel to
Asia. Prevalence of QRNG in Hawaii steadily increased
from 1997 to 2001 (2,3). In 2000, California reported
QRNG in San Francisco, San Diego, and Orange County.
In 2001, 33 (2.5%) of 1,311 of isolates tested in California
were resistant to fluoroquinolones; this increase continued
in 2002 (4,5). As a result of the increasing prevalence of
QRNG, the Hawaii Department of Health and California
Department of Health Services recommended that clini-
cians avoid using fluoroquinolones when treating gonor-
rhea (6). Because of QRNG prevalence variation in
countries outside of the United States, CDC recommended
in its 2002 STD Treatment Guidelines that fluoro-
quinolones not be used to treat gonorrhea acquired in Asia,
the Pacific Islands, Hawaii, California, or other areas with
an increased prevalence of QRNG (6–9).
In addition to Hawaii and California, low numbers of
QRNG-resistant isolates had been reported from cities in
the United States before 2000 (4,5). GISP data for 2003
showed resistant isolates from Cleveland, Baltimore,
Chicago, Dallas, and Kansas, with a significant increase in
QRNG in Seattle, New York City, Massachusetts,
California, and Michigan, and smaller increases in Phoenix,
Minneapolis, Chicago, Las Vegas, and Portland (1). 
The primary therapies currently recommended by CDC
for uncomplicated gonococcal infections of the cervix,
urethra, and rectum include ceftriaxone, cefixime, or a flu-
oroquinolone (ciprofloxacin, levofloxacin, or ofloxacin)
(6). In July of 2002, Wyeth Pharmaceuticals stopped man-
ufacturing cefixime, the only recommended oral
cephalosporin; company inventories were fully depleted
by October 2002 (10). Michigan used only cefixime
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Although the US Food and Drug Administration has
approved cefpodoxime and cefuroxime axetil to treat
uncomplicated gonococcal infections, CDC has not recom-
mended either of these oral cephalosporins to replace
cefixime because they fail to meet CDC’s efficacy stan-
dards (10).
CDC recommended, in 2002, that state health depart-
ments monitor local antimicrobial drug–susceptibility pat-
terns to guide local treatment recommendations (3). In
response, the Michigan Department of Community Health
(MDCH) established a sentinel surveillance system to
monitor the prevalence of drug-resistant gonorrhea, char-
acterize patients with drug-resistant infections, and pro-
vide local treatment recommendations in Michigan. Before
2003, only sporadic cases of QRNG were detected in
Michigan; all of these patients acquired their infections
during foreign travel. However, resistant strains might
have gone undetected, as an estimated 97% of genital gon-
orrhea testing in Michigan is performed by nucleic acid
testing, from which viable isolates for susceptibility testing
cannot be obtained (MDCH, unpub. data). To augment
routine susceptibility studies performed at MDCH, a spe-
cial surveillance project to collect gonococcal isolates
from clinical laboratories across the state was initiated in
July 2002 and continued through September 2004. We
describe the development of this surveillance project, dis-
cuss the challenges of maintaining surveillance on a volun-
tary basis, and present data collected from the project.
Methods and Materials
Selection of Participating Sites
Although ≈110 clinical laboratories in Michigan offer
comprehensive microbiology services, many have
switched to nucleic acid methods. To determine the num-
ber of laboratories that perform genital gonorrhea cultures
as their routine detection method, positive gonorrhea case
reports submitted to the state health department during a
representative 3-month period (August–October 2001)
were examined to obtain a convenience sample of labora-
tories that culture genital specimens for gonorrhea.
Nineteen laboratories reported >1 culture-based positive
results during that time. These laboratories were contacted
to determine the average number of cultures positive for
gonorrhea per year, whether cultures were performed on
genital specimens, whether genital gonorrhea cultures
were expected to continue to be collected for the next 6
months, and whether the laboratory was willing to submit
isolates for surveillance. Of the 19 laboratories, 5 clinical
(hospital) laboratories were identified that recovered >10
genital gonorrhea cultures each month; all 5 agreed to par-
ticipate as sentinel sites. These 5 laboratories were located
in 5 different counties (Table 1). The state health depart-
ment laboratory also received routine gonorrhea cultures
from a local health department STD clinic and occasional-
ly referred N. gonorrhoeae isolates for identification or
susceptibility testing. These cultures were also included in
the surveillance system. After the identification of QRNG
cases, surveillance was expanded to include 4 additional
STD clinics in 4 counties (Table 1).
Isolation, Identification, and Susceptibility Testing
Laboratories were provided with chocolate agar slants
(Remel, Lenexa, KS, USA), International Air Transport
Association–compliant mailing containers, and specific
instructions for packaging and shipping. Courier pickup of
isolates on an on-call basis was also arranged. Isolates
were accepted on chocolate agar slants or frozen in
Trypticase soy broth with glycerol.
Gonococcal isolates from genital and nongenital cul-
tures either were recovered from cultures collected by the
local health department STD clinic or were referred from
the sentinel sites or other clinical laboratories. Cultures
obtained from the local STD clinic were plated onto
Modified Thayer-Martin medium (Becton Dickinson,
Cockeysville, MD, USA) and incubated for 18 to 24 h at
35°C in a candle jar before transport to MDCH. At MDCH,
the plates were incubated an additional 48 h at 35°C in 5%
to 10% CO2 and examined daily. Suspect colonies grown
on Thayer-Martin medium and referred isolates were pre-
sumptively identified by Gram stain and oxidase reaction.
The isolates were subcultured on chocolate agar (Remel)
for further testing. All isolates were frozen in skim milk at
–70°C. 
Isolates were identified by using the apiNH system
(bioMérieux, Inc., Durham, NC, USA). If an isolate was
not identified by apiNH, conventional biochemical tests
were performed, including cystine tryptic agar sugar fer-
mentation test with glucose, sucrose, maltose, and lactose. 
Antimicrobial drug susceptibility for ciprofloxacin,
spectinomycin, tetracycline, ceftriaxone, and cefixime or
cefpodoxime was determined by disk diffusion on gono-
coccal (GC) agar base supplemented with 1% GCHI
enrichment (Remel) according to the Clinical and
Laboratory Standards Institute (formerly NCCLS) proce-
dure (11). Any isolate categorized as repeatedly resistant to
or intermediately resistant to ciprofloxacin was tested to
determine MIC (12). MIC was determined by Etest (AB
BIODISK North America, Piscataway, NJ, USA) on GC
Agar Base supplemented with 1% GCHI enrichment,
according to the manufacturer’s instructions (13).
N. gonorrhoeae ATCC 492226 was used as the quality
control strain for both disk diffusion and Etest. Beginning
January 1, 2004, MDCH added cefpodoxime and deleted
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gonorrhea. 
Epidemiologic Analysis
Final reports of susceptibility results were distributed to
the submitting laboratory and to the MDCH Bureau of
Epidemiology. For cases with susceptibility testing results
reported from January 2003 to September 2004, provider
information was obtained from the submitting laboratory.
Demographic, behavioral, and clinical data were solicited
from the patients’ healthcare providers. For all gonorrhea
patients, each provider was contacted to give permission to
receive a data collection form by secure fax. The form col-
lected information on reason for visit, zip code, age, race,
ethnicity, sex, sexual orientation, prior gonorrhea infec-
tion, primary therapies for gonorrhea and chlamydia, and
the reason a culture was performed. The completed forms
were faxed back to the Bureau of Epidemiology, where
epidemiologic and laboratory data were entered into a
Microsoft Access database (Microsoft Corp., Redmond,
WA, USA). Patients with QRNG were interviewed (by
phone or in person) by MDCH disease intervention spe-
cialists, and additional information was collected, includ-
ing that on illicit drug use, recent use of antimicrobial
agents, sexual partner risk factors, HIV status, and travel
history. Prevalence ratios were used to examine the associ-
ations between QRNG and demographic, behavioral, and
clinical characteristics. Data were analyzed with SAS ver-
sion 9.1 (SAS Institute, Inc., Cary, NC, USA). The project
was determined to be routine surveillance activity and thus
exempt from human subjects review by the MDCH
Institutional Review Board. 
Results
From January 1, 2003, to September 30, 2004, suscep-
tibility testing results for 1,122 isolates (from 1,074
patients) were reported. Patient and specimen characteris-
tics for QRNG and non-QRNG isolates are shown in
Table 2, stratified by year. Atotal of 582 isolates (from 564
patients) obtained by disk diffusion were reported during
calendar year 2003. All isolates were susceptible to
cefixime, ceftriaxone, and spectinomycin; 43 (7.4%) were
resistant to tetracycline. Seventeen (2.9%) isolates were
resistant to ciprofloxacin (MIC >1 µg/mL), and 1 (0.2%)
showed intermediate resistance (MIC 0.12–0.5 µg/mL).
The 17 ciprofloxacin-resistant isolates in 2003 represented
14 individual cases of QRNG. Table 3 lists 2003 and 2004
QRNG cases with relevant risk factors and demographics.
In 2003, 11 patients were male. Patients ranged in age from
16 to 45 years (median 26). Nearly half of the QRNG
patients were white (43%). Four of the 11 male patients
were men who have sex with men (MSM). Alarge number
of cases (57%) were detected at public STD clinics in
county A.
From January 1 to September 30, 2004, a total of 540
(510 patients) isolates whose susceptibilities were meas-
ured by disk diffusion showed no resistance to cefpo-
doxime, ceftriaxone, and spectinomycin. Eight isolates
(1.5%) were resistant to ciprofloxacin, and 1 (0.2%) isolate
had intermediate resistance. Resistance to tetracycline was
similar to that seen in the previous year. All 8 cases of
QRNG detected in the 2004 study period were in MSM.
Patients ranged from 20 to 43 years of age (median 26).
Most were white (88%), and more than half (63%) were
detected at clinic B, a public STD clinic in a county not
contiguous to clinic A. 
Cumulative distribution, for the entire study period, of
the submissions by site are shown in Table 1. Fifteen per-
cent (158/1,074) of all gonococcal isolates were submitted
by emergency rooms, 19% (205/1,074) were from primary
medical doctors, and 64% (692/1,074) were from STD
clinics. Although 35% of isolates were submitted by pri-
vate providers, only 23% of QRNG cases were identified
through those venues. Most QRNG cases were identified
through public STD clinics (77%). The overall return rate
of the data collection form from healthcare providers was
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request for patient information; STD clinics and private
medical doctors had higher response rates (93% and 72%,
respectively) than emergency rooms (55%). 
Although most persons with gonorrhea in our sentinel
surveillance system are African American (76% of those
with known race), the prevalence of QRNG was higher
among whites, 7% versus 1% among non-whites. The
prevalence ratio was 1.07 (p<0.0001, 95% confidence
interval 1.02–1.11) (Table 4). The prevalence of QRNG
was higher among those >40 years of age, 4% versus 2%
among those <40 years of age. MSM constituted 11% of
all gonorrhea patients in the surveillance system, but they
accounted for 63% of male QRNG patients; heterosexuals
comprised 37% of the male QRNG patients. The preva-
lence of QRNG was highest for MSM (14%) and was rel-
atively low for heterosexual men (1%) and women (1%).
The presence of symptoms was not associated with
quinolone-resistant infections, as the prevalence of QRNG
was similar between both those with and without symp-
toms. Prior history of gonorrhea was not significantly
associated with QRNG; the prevalence of QRNG among
those with a history of gonorrhea was 2%, versus 3%
among those without a history of gonorrhea. Table 5 shows
enhanced variables, such as drug use, travel history, and
HIV status, collected from interviews conducted with
QRNG patients. Most QRNG patients reported no recent
use of antimicrobial agents, no illicit drug use, and no
recent travel. These findings also held true for sex partner
characteristics, although sex partners had an increased
percentage of illicit drug use and a higher percentage of
unknown responses. Three of the 22 QRNG patients dur-
ing the study period were HIV-positive.
Discussion
Michigan has seen a higher prevalence of QRNG in
recent years among heterosexuals, especially men in coun-
ty A (3.4%), compared to other surveillance sites, such as
New York and Massachusetts (1.6% and 1.8%, respective-
ly) (14). Shortly after sentinel surveillance was instituted,
a geographic cluster of QRNG cases was discovered
among a group of heterosexual teenagers in clinic A. A
sexual link from 1 QRNG patient to another was discov-
ered in only half of the patients. How QRNG initially
emerged in this population is still unclear, as none of these
heterosexual patients had a travel history. In cooperation
with MDCH, the local health departments in county A
(where the patients resided) and in the 5 contiguous coun-
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Before this recommendation, 71% of clinic Apatients were
treated with ciprofloxacin. After the recommendation was
implemented, only 7% received ciprofloxacin as their pri-
mary treatment, according to clinic records. 
A quick response to this geographic cluster may have
halted the spread of QRNG in the community. However,
at clinic A the direct costs of treatment increased, since
250 mg of intramuscular ceftriaxone costs nearly 3 times
more than a 500-mg dose of ciprofloxacin (US $12.85 vs.
$4.14). Indirect costs associated with staffing and
increased amounts of time spent per patient (since all
were treated with ceftriaxone and all had isolates submit-
ted for culture) also increased but were not calculated.
After 18 months without any cases, despite continued sur-
veillance, the quinolone use ban on all patients (excluding
MSM, per the revised STD treatment guidelines) was lift-
ed, and no additional cases have since been reported. In
addition, a cluster of cases in MSM in county B led local
officials to make several recommendations for MSM,
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importance of asking about patients’ sexual orientation,
avoiding quinolone use, and using culture to diagnose
gonorrhea. 
During this surveillance project, 2 clusters were identi-
fied in 2 counties. However, QRNG surveillance is limited
and not optimally representative: during the study period,
it only operated in 9 of Michigan’s 83 counties. This sur-
veillance system captured only 4.4% of the total gonorrhea
cases in Michigan; however, the counties represented in
this surveillance system, in addition to the surveillance in
Detroit City for the GISP project, report 38% of
Michigan’s gonorrhea cases. Those patients in the surveil-
lance system are more likely to be seen at a public STD
clinic (67% of those in the surveillance system vs. 23% of
those in statewide morbidity reports), be African American
(76% of the surveillance system vs. 40% of statewide mor-
bidity), and male (67% of those in surveillance system vs.
44% of statewide gonorrhea case-patients). The Detroit
City Health Department joined the GISP project in 2003,
and no isolates collected from that site have been resistant
to fluoroquinolones. This finding suggests that surveil-
lance isolates should be collected from multiple geograph-
ic sites, ideally with demographic diversity, to demonstrate
emerging resistance. 
The fastidious nature of N. gonorrhoeae presented
some challenges for the submitting laboratories.
Approximately 10% of the total isolates received were
either nonviable on subculture or overgrown with other
organisms and were reported as unsatisfactory. At the end
of December 2003, three of the 5 clinical laboratories
stopped sending isolates to MDCH, citing economic and
staffing barriers. Since QRNG prevalence was highest
among patients seeking care from public STD clinics,
MDCH asked additional public clinics to collect cultures.
At the end of the study period, cultures were submitted by
5 local health departments and 2 private healthcare
providers (a student health center and a major urban hospi-
tal laboratory).
MDCH will continue to provide routine N. gonorrhoeae
susceptibility testing to monitor the emergence of resistance
when isolates are available. Clinical laboratories are also
encouraged to submit positive cultures to MDCH for sus-
ceptibility testing. To improve surveillance efforts, MDCH
has recommended that clinicians culture specimens from
patients with persistent symptoms. Clinical laboratories are
asked to assist by submitting isolates for susceptibility test-
ing from patients who are repeatedly culture-positive.
However, as nucleic acid amplification tests replace culture-
based methods, molecular techniques to demonstrate resist-
ance and identify clusters will need to be developed.
Although Michigan’s data are not geographically repre-
sentative, the state’s sentinel surveillance system is strong
because numerator and denominator data are collected,
allowing for the calculation of true prevalence ratios. The
continued emergence of QRNG among gonorrhea cases
will be a major financial limitation to state STD programs.
Quinolones are currently the only oral treatment for gonor-
rhea recommended by CDC, and intramuscular ceftriaxone
costs nearly 3 times more than a dose of ciprofloxacin.
Since approximately one third of Michigan’s estimated
17,000 gonorrhea patients in 2004 were treated in public
clinics, the cost of QRNG will substantially limit the serv-
ices the Michigan STD program can provide to residents.
This study illustrates that, although a local ban on
ciprofloxacin use in response to a QRNG cluster demand-
ed more intensive resources for 1 Michigan county, the
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